Zobrazeno 1 - 10
of 128
pro vyhledávání: '"Kjell S. Sakariassen"'
Autor:
Masahiro Murakami, Kazunori Otsui, Yoshinobu Ijiri, Muneshige Shimizu, Hideo Ikarugi, Wataru Shioyama, Junichiro Yamamoto, Kjell S Sakariassen
Publikováno v:
Future Science OA, Vol 8, Iss 3 (2022)
Because of the high mortality from myocardial infarction and stroke, there is a great demand for finding novel methods of diagnosis, prevention and treatment of these diseases. Most of the current tests measure important determinants of thrombosis su
Externí odkaz:
https://doaj.org/article/71573bd8f74f4b08a03edc4dc922d3d7
Autor:
Junichiro Yamamoto, Nobutaka Inoue, Kazunori Otsui, Hideo Ikarugi, Muneshige Shimizu, Shinji Yamamoto, Masahiro Murakami, Yoshinobu Ijiri, Kjell S Sakariassen
Publikováno v:
Future Science OA, Vol 5, Iss 6 (2019)
Externí odkaz:
https://doaj.org/article/a7f860664cda4e73a3bc0ab7ba361230
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 17(9)
Autor:
Shinji Yamamoto, Junichiro Yamamoto, Kjell S Sakariassen, Masahiro Murakami, Yoshinobu Ijiri, Nobutaka Inoue, Kazunori Otsui, Hideo Ikarugi, Muneshige Shimizu
Publikováno v:
Future Science OA
Autor:
Hideo Ikarugi, Muneshige Shimizu, Yoshinobu Ijiri, Shinji Yamamoto, Junichiro Yamamoto, Kjell S Sakariassen
Publikováno v:
Future Science OA
Publikováno v:
Future Science OA
The Science for Life Laboratory Drug Discovery and Development Platform (SciLifeLab DDD) was established in Stockholm and Uppsala, Sweden, in 2014. It is one of ten platforms of the Swedish national SciLifeLab which support projects run by Swedish ac
Autor:
Bhaloo Desai, Ana Muniz-Lozano, Andrew Darlington, Norbert Bender, Ryan E. Wilson, Kjell S. Sakariassen, Ronakkumar Patel, Fabiana Rollini, Francesco Franchi, Dominick J. Angiolillo, Antonio Tello-Montoliu
Publikováno v:
Journal of Thrombosis and Thrombolysis. 37:131-138
Patients with diabetes mellitus (DM) have increased propensity to generate thromboxane A2 (TXA2) and other eicosanoids which can contribute to their heightened platelet reactivity. EV-077 is a potent thromboxane receptor antagonist and thromboxane sy
Autor:
Kjell S Sakariassen, Pēteris Alberts, Jean-Philippe Meyer, Alexandra Santana Sorensen, A. Richardson
Publikováno v:
European Journal of Clinical Pharmacology. 69:459-465
This study was performed to determine the oral pharmacokinetics (PK) of EV-077 and its effects on pharmacodynamic (PD) markers. EV-077 blocks prostanoid-induced and isoprostane-induced cellular activation, and is in development for the treatment of v
Autor:
Bill Davis, Gavin E. Jarvis, Nicholas Pugh, Kjell S. Sakariassen, Richard W. Farndale, Annelize Koch
Publikováno v:
Journal of Thrombosis and Thrombolysis. 33:6-15
This study was designed to assess the effect of Factor Xa antagonists on thrombus formation at various axial positions on a tissue factor rich surface under arterial blood flow conditions. Non-anticoagulated, flowing human blood, drawn directly from
Autor:
Junichiro Yamamoto, Hideo Ikarugi, Yoshinobu Ijiri, Kazunori Otsui, Nobutaka Inoue, Kjell S Sakariassen
Publikováno v:
Future Science OA
Prevention of thrombotic disorders has priority over treatment. There are only two pathologically relevant tests which are suitable for measuring the overall thrombotic status both in experimental conditions and in humans. The Global Thrombosis Test